Adipose derived mesenchymal stem cell therapy in the treatment of isolated knee chondral lesions: design of a randomised controlled pilot study comparing arthroscopic microfracture versus arthroscopic microfracture combined with postoperative mesenchymal stem cell injections
| Autor: | Flavia M. Cicuttini, Leesa Huguenin, Kiran Shah, D. Bates, Yuanyuan Wang, Cameron Norsworthy, Richard L. Boyd, Jon J. Ford, Julien Freitag, Andrew J. Hahne |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Cartilage Articular medicine.medical_specialty Adolescent Knee Joint Pilot Projects Knee Injuries Osteoarthritis Transplantation Autologous law.invention Young Adult Clinical Protocols Randomized controlled trial law Internal medicine Protocol medicine Humans Prospective Studies Sports and Exercise Medicine Autologous chondrocyte implantation Prospective cohort study business.industry Mesenchymal stem cell Mesenchymal Stem Cells General Medicine Middle Aged Osteoarthritis Knee medicine.disease Rheumatology Surgery Clinical trial Transplantation Adipose Tissue Research Design business Cartilage Diseases |
| Zdroj: | BMJ Open |
| ISSN: | 2044-6055 |
| DOI: | 10.1136/bmjopen-2015-009332 |
| Popis: | Introduction The management of intra-articular chondral defects in the knee remains a challenge. Inadequate healing in areas of weight bearing leads to impairment in load transmission and these defects predispose to later development of osteoarthritis. Surgical management of full thickness chondral defects include arthroscopic microfracture and when appropriate autologous chondrocyte implantation. This latter method however is technically challenging, and may not offer significant improvement over microfracture. Preclinical and limited clinical trials have indicated the capacity of mesenchymal stem cells to influence chondral repair. The aim of this paper is to describe the methodology of a pilot randomised controlled trial comparing arthroscopic microfracture alone for isolated knee chondral defects versus arthroscopic microfracture combined with postoperative autologous adipose derived mesenchymal stem cell injections. Methods and analysis A pilot single-centre randomised controlled trial is proposed. 40 participants aged 18–50 years, with isolated femoral condyle chondral defects and awaiting planned arthroscopic microfracture will be randomly allocated to a control group (receiving no additional treatment) or treatment group (receiving postoperative adipose derived mesenchymal stem cell treatment). Primary outcome measures will include MRI assessment of cartilage volume and defects and the Knee Injury and Osteoarthritis Outcome Score. Secondary outcomes will include further MRI assessment of bone marrow lesions, bone area and T2 cartilage mapping, a 0–10 Numerical Pain Rating Scale, a Global Impression of Change score and a treatment satisfaction scale. Adverse events and cointerventions will be recorded. Initial outcome follow-up for publication of results will be at 12 months. Further annual follow-up to assess long-term differences between the two group will occur. Ethics and dissemination This trial has received prospective ethics approval through the Latrobe University Human Research Ethics Committee. Dissemination of outcome data is planned through both national and international conferences and formal publication in a peer-reviewed journal. Trial registration number Australia and New Zealand Clinical Trials Register (ANZCTR Trial ID: ACTRN12614000812695). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|